Mustang Bio (MBIO) Change in Interest Receivables (2017 - 2018)
Mustang Bio (MBIO) posted quarterly Change in Interest Receivables of $34000.0 for Q4 2018, down 52.11% year-over-year from $71000.0 in Q4 2017, and up 111.26% quarter-over-quarter from -$302000.0 in Q3 2018.
Mustang Bio (MBIO) Change in Interest Receivables (2017 - 2018) Analysis & Trends
Mustang Bio (MBIO) has reported Change in Interest Receivables for 2 consecutive years, with $34000.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Change in Interest Receivables fell 52.11% year-over-year to $34000.0; the TTM figure through Dec 2019 stood at -$62000.0 (down 277.14% YoY), while the FY2018 annual figure was $35000.0, down 66.98% from the prior year.
- Change in Interest Receivables climbed to $34000.0 in Q4 2018 per MBIO's latest filing, from -$302000.0 in the prior quarter.
- Across five years, Change in Interest Receivables topped out at $206000.0 in Q2 2018 and bottomed at -$302000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 34,000.00 |
| Sep 30, 2018 | -302,000.00 |
| Jun 30, 2018 | 206,000.00 |
| Mar 31, 2018 | 97,000.00 |
| Dec 31, 2017 | 71,000.00 |
| Sep 30, 2017 | 35,000.00 |